The microneedle flu vaccine market size has grown rapidly in recent years. It will grow from $1.66 billion in 2025 to $1.82 billion in 2026 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to increasing global influenza vaccination programs, advances in transdermal drug delivery research, expansion of public immunization initiatives, early clinical trials of microneedle platforms, rising demand for minimally invasive vaccines.
The microneedle flu vaccine market size is expected to see rapid growth in the next few years. It will grow to $2.67 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to increasing investments in next-generation vaccine technologies, rising focus on pandemic preparedness, expansion of decentralized vaccination models, growing adoption in pediatric and elderly populations, increasing regulatory approvals for microneedle platforms. Major trends in the forecast period include increasing development of painless vaccine delivery systems, rising adoption of self-administered vaccination methods, growing focus on cold-chain-free vaccine formats, expansion of large-scale immunization programs, enhanced emphasis on patient compliance.
The increasing prevalence of needle phobia is expected to drive the growth of the microneedle flu vaccine market. Needle phobia, also known as trypanophobia, is an intense fear or anxiety triggered by the sight, sensation, or anticipation of needle-based procedures, often leading individuals to avoid necessary medical interventions. This condition is primarily fueled by psychological sensitivity and negative past experiences, creating long-term fear and avoidance behavior. Microneedle flu vaccines provide a minimally invasive and nearly painless alternative, which reduces psychological barriers to vaccination and encourages better patient compliance. For example, in February 2025, the American Society for Clinical Pathology (ASCP) reported that approximately 50% to 60% of children experience needle phobia, with the fear being most prevalent between the ages of 4 and 6. As a result, the growing prevalence of needle phobia is contributing to the expansion of the microneedle flu vaccine market.
Leading companies in the microneedle flu vaccine market are focusing on securing investments to accelerate the development of patch-based RNA vaccines. These efforts support early-stage research and collaboration, advancing next-generation vaccine delivery technologies. For example, in March 2024, the Biomedical Advanced Research and Development Authority (BARDA), a U.S.-based government agency, announced a $50 million investment through the Patch Forward Prize to fast-track the development of microneedle patch-based RNA vaccines targeting influenza and COVID-19. This initiative aims to drive innovation by funding concept development and supporting the progression of combination products into Phase I clinical trials. The program fosters collaboration between vaccine developers and patch manufacturers, with the goal of overcoming technical and regulatory challenges, improving vaccine accessibility, and bolstering national preparedness for infectious diseases.
In January 2024, Gylden Pharma Limited (formerly Emergex Vaccines Holding Limited), a UK-based clinical-stage biotechnology company, partnered with DEKA Research & Development Corp. to enhance patient-friendly drug delivery through advanced microneedle-based intradermal administration technologies. The collaboration seeks to evaluate the compatibility and effectiveness of combining Emergex’s immunotherapeutic candidates with DEKA’s microneedle applicator for potential clinical use. DEKA Research & Development Corp., a U.S.-based company specializing in microneedle solutions, will play a pivotal role in advancing this technology.
Major companies operating in the microneedle flu vaccine market are Merck & Co. Inc., Sanofi SA, GlaxoSmithKline plc, Seqirus, Vaxxas, Micron Biomedical Inc., Vaxess Technologies, Debiotech S.A., NanoPass Technologies Limited, Microdermics Inc., Micropoint Technologies Pte Ltd., CosMED Pharmaceutical Co. Ltd., TSRL Inc., Corium International, Becton Dickinson and Company (BD), AptarGroup, FluGen Inc., 3M Drug Delivery Systems, Nitto Denko Corporation, Zosano Pharma Corporation, Camurus AB, Raphas Co. Ltd.
North America was the largest region in the microneedle flu vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the microneedle flu vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the microneedle flu vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the microneedle flu vaccine market by increasing costs of imported biopolymers, microfabrication equipment, pharmaceutical excipients, and sterile packaging components. Vaccine manufacturers in North America and Europe are most affected due to reliance on specialized imported materials, while Asia-Pacific faces cost pressure on export-oriented vaccine production. These tariffs are increasing development and scale-up costs. However, they are also encouraging domestic manufacturing of microneedle platforms, regional supply chain localization, and innovation in cost-effective vaccine delivery technologies.
The microneedle flu vaccine market research report is one of a series of new reports that provides microneedle flu vaccine market statistics, including microneedle flu vaccine industry global market size, regional shares, competitors with a microneedle flu vaccine market share, detailed microneedle flu vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the microneedle flu vaccine industry. This microneedle flu vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The microneedle flu vaccine is an innovative vaccination method that uses a small, patch-like array of microscopic needles to painlessly deliver the influenza vaccine into the skin. This approach offers a minimally invasive, efficient, and user-friendly alternative to traditional intramuscular injections. It is designed to enhance vaccine accessibility, increase patient compliance, facilitate self-administration, and improve immunization coverage, especially in large-scale public health initiatives.
The main product types of microneedle flu vaccines include hollow microneedles, solid microneedles, coated microneedles, and dissolving microneedles. A hollow microneedle is a micro-scale needle with a central lumen, allowing for the direct injection of liquid formulations into the skin. These vaccines can be administered through various routes, such as oral, parenteral, and nasal, and are distributed through several channels, including hospital pharmacies, retail pharmacies, and online pharmacies. Applications for these vaccines include flu vaccination, seasonal flu prevention, pediatric vaccines, and vaccines for the elderly.
The microneedle flu vaccine market consists of sales of polymer-based microneedle patches, hydrogel-forming microneedles, silicon microneedle arrays, biodegradable microneedle systems, metallic microneedles, and lipid-based microneedle formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The microneedle flu vaccine market size is expected to see rapid growth in the next few years. It will grow to $2.67 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to increasing investments in next-generation vaccine technologies, rising focus on pandemic preparedness, expansion of decentralized vaccination models, growing adoption in pediatric and elderly populations, increasing regulatory approvals for microneedle platforms. Major trends in the forecast period include increasing development of painless vaccine delivery systems, rising adoption of self-administered vaccination methods, growing focus on cold-chain-free vaccine formats, expansion of large-scale immunization programs, enhanced emphasis on patient compliance.
The increasing prevalence of needle phobia is expected to drive the growth of the microneedle flu vaccine market. Needle phobia, also known as trypanophobia, is an intense fear or anxiety triggered by the sight, sensation, or anticipation of needle-based procedures, often leading individuals to avoid necessary medical interventions. This condition is primarily fueled by psychological sensitivity and negative past experiences, creating long-term fear and avoidance behavior. Microneedle flu vaccines provide a minimally invasive and nearly painless alternative, which reduces psychological barriers to vaccination and encourages better patient compliance. For example, in February 2025, the American Society for Clinical Pathology (ASCP) reported that approximately 50% to 60% of children experience needle phobia, with the fear being most prevalent between the ages of 4 and 6. As a result, the growing prevalence of needle phobia is contributing to the expansion of the microneedle flu vaccine market.
Leading companies in the microneedle flu vaccine market are focusing on securing investments to accelerate the development of patch-based RNA vaccines. These efforts support early-stage research and collaboration, advancing next-generation vaccine delivery technologies. For example, in March 2024, the Biomedical Advanced Research and Development Authority (BARDA), a U.S.-based government agency, announced a $50 million investment through the Patch Forward Prize to fast-track the development of microneedle patch-based RNA vaccines targeting influenza and COVID-19. This initiative aims to drive innovation by funding concept development and supporting the progression of combination products into Phase I clinical trials. The program fosters collaboration between vaccine developers and patch manufacturers, with the goal of overcoming technical and regulatory challenges, improving vaccine accessibility, and bolstering national preparedness for infectious diseases.
In January 2024, Gylden Pharma Limited (formerly Emergex Vaccines Holding Limited), a UK-based clinical-stage biotechnology company, partnered with DEKA Research & Development Corp. to enhance patient-friendly drug delivery through advanced microneedle-based intradermal administration technologies. The collaboration seeks to evaluate the compatibility and effectiveness of combining Emergex’s immunotherapeutic candidates with DEKA’s microneedle applicator for potential clinical use. DEKA Research & Development Corp., a U.S.-based company specializing in microneedle solutions, will play a pivotal role in advancing this technology.
Major companies operating in the microneedle flu vaccine market are Merck & Co. Inc., Sanofi SA, GlaxoSmithKline plc, Seqirus, Vaxxas, Micron Biomedical Inc., Vaxess Technologies, Debiotech S.A., NanoPass Technologies Limited, Microdermics Inc., Micropoint Technologies Pte Ltd., CosMED Pharmaceutical Co. Ltd., TSRL Inc., Corium International, Becton Dickinson and Company (BD), AptarGroup, FluGen Inc., 3M Drug Delivery Systems, Nitto Denko Corporation, Zosano Pharma Corporation, Camurus AB, Raphas Co. Ltd.
North America was the largest region in the microneedle flu vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the microneedle flu vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the microneedle flu vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the microneedle flu vaccine market by increasing costs of imported biopolymers, microfabrication equipment, pharmaceutical excipients, and sterile packaging components. Vaccine manufacturers in North America and Europe are most affected due to reliance on specialized imported materials, while Asia-Pacific faces cost pressure on export-oriented vaccine production. These tariffs are increasing development and scale-up costs. However, they are also encouraging domestic manufacturing of microneedle platforms, regional supply chain localization, and innovation in cost-effective vaccine delivery technologies.
The microneedle flu vaccine market research report is one of a series of new reports that provides microneedle flu vaccine market statistics, including microneedle flu vaccine industry global market size, regional shares, competitors with a microneedle flu vaccine market share, detailed microneedle flu vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the microneedle flu vaccine industry. This microneedle flu vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The microneedle flu vaccine is an innovative vaccination method that uses a small, patch-like array of microscopic needles to painlessly deliver the influenza vaccine into the skin. This approach offers a minimally invasive, efficient, and user-friendly alternative to traditional intramuscular injections. It is designed to enhance vaccine accessibility, increase patient compliance, facilitate self-administration, and improve immunization coverage, especially in large-scale public health initiatives.
The main product types of microneedle flu vaccines include hollow microneedles, solid microneedles, coated microneedles, and dissolving microneedles. A hollow microneedle is a micro-scale needle with a central lumen, allowing for the direct injection of liquid formulations into the skin. These vaccines can be administered through various routes, such as oral, parenteral, and nasal, and are distributed through several channels, including hospital pharmacies, retail pharmacies, and online pharmacies. Applications for these vaccines include flu vaccination, seasonal flu prevention, pediatric vaccines, and vaccines for the elderly.
The microneedle flu vaccine market consists of sales of polymer-based microneedle patches, hydrogel-forming microneedles, silicon microneedle arrays, biodegradable microneedle systems, metallic microneedles, and lipid-based microneedle formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Microneedle Flu Vaccine Market Characteristics
3. Microneedle Flu Vaccine Market Supply Chain Analysis
4. Global Microneedle Flu Vaccine Market Trends and Strategies
5. Microneedle Flu Vaccine Market Analysis of End Use Industries
7. Global Microneedle Flu Vaccine Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Microneedle Flu Vaccine Total Addressable Market (TAM) Analysis for the Market
9. Microneedle Flu Vaccine Market Segmentation
10. Microneedle Flu Vaccine Market Regional and Country Analysis
11. Asia-Pacific Microneedle Flu Vaccine Market
12. China Microneedle Flu Vaccine Market
13. India Microneedle Flu Vaccine Market
14. Japan Microneedle Flu Vaccine Market
15. Australia Microneedle Flu Vaccine Market
16. Indonesia Microneedle Flu Vaccine Market
17. South Korea Microneedle Flu Vaccine Market
18. Taiwan Microneedle Flu Vaccine Market
19. South East Asia Microneedle Flu Vaccine Market
20. Western Europe Microneedle Flu Vaccine Market
21. UK Microneedle Flu Vaccine Market
22. Germany Microneedle Flu Vaccine Market
23. France Microneedle Flu Vaccine Market
24. Italy Microneedle Flu Vaccine Market
25. Spain Microneedle Flu Vaccine Market
26. Eastern Europe Microneedle Flu Vaccine Market
27. Russia Microneedle Flu Vaccine Market
28. North America Microneedle Flu Vaccine Market
29. USA Microneedle Flu Vaccine Market
30. Canada Microneedle Flu Vaccine Market
31. South America Microneedle Flu Vaccine Market
32. Brazil Microneedle Flu Vaccine Market
33. Middle East Microneedle Flu Vaccine Market
34. Africa Microneedle Flu Vaccine Market
36. Microneedle Flu Vaccine Market Competitive Landscape and Company Profiles
37. Microneedle Flu Vaccine Market Other Major and Innovative Companies
40. Microneedle Flu Vaccine Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Microneedle Flu Vaccine Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses microneedle flu vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for microneedle flu vaccine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The microneedle flu vaccine market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Hollow Microneedle; Solid Microneedle; Coated Microneedle; Dissolving Microneedle2) By Route Of Administration: Transdermal; Intradermal
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By Application: Flu Vaccination; Seasonal Flu Prevention; Pediatric Vaccines; Elderly Vaccines
Subsegments:
1) By Hollow Microneedle: Single-Use Hollow Microneedles; Pre-Filled Disposable Microneedles; Polymer-Based Hollow Microneedles; Silicon-Based Hollow Microneedles2) By Solid Microneedle: Metal Solid Microneedles; Silicon Solid Microneedles; Polymer Solid Microneedles
3) By Coated Microneedle: Antigen-Coated Microneedles; Vaccine-Coated Microneedles; Biodegradable Coated Microneedles; Nano-Coated Microneedles
4) By Dissolving Microneedle: Fast-Dissolving Microneedles; Slow-Release Microneedles; Hydrogel-Based Dissolving Microneedles; Sugar-Based Dissolving Microneedles
Companies Mentioned: Merck & Co. Inc.; Sanofi SA; GlaxoSmithKline plc; Seqirus; Vaxxas; Micron Biomedical Inc.; Vaxess Technologies; Debiotech S.A.; NanoPass Technologies Limited; Microdermics Inc.; Micropoint Technologies Pte Ltd.; CosMED Pharmaceutical Co. Ltd.; TSRL Inc.; Corium International; Becton Dickinson and Company (BD); AptarGroup; FluGen Inc.; 3M Drug Delivery Systems; Nitto Denko Corporation; Zosano Pharma Corporation; Camurus AB; Raphas Co. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Microneedle Flu Vaccine market report include:- Merck & Co. Inc.
- Sanofi SA
- GlaxoSmithKline plc
- Seqirus
- Vaxxas
- Micron Biomedical Inc.
- Vaxess Technologies
- Debiotech S.A.
- NanoPass Technologies Limited
- Microdermics Inc.
- Micropoint Technologies Pte Ltd.
- CosMED Pharmaceutical Co. Ltd.
- TSRL Inc.
- Corium International
- Becton Dickinson and Company (BD)
- AptarGroup
- FluGen Inc.
- 3M Drug Delivery Systems
- Nitto Denko Corporation
- Zosano Pharma Corporation
- Camurus AB
- Raphas Co. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.82 Billion |
| Forecasted Market Value ( USD | $ 2.67 Billion |
| Compound Annual Growth Rate | 10.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
